For the first 5 years, RAP was a research company seeking validations and regulatory approvals for its technology. Very similar in fashion to pharmaceutical company developing a new drug.
Only since late last year it enters the commercial stage, less than 12 months. I can't think of any company on or off the ASX that makes a motza in their first year of trading.
I think we need to put that in perspective. I too have to constantly remind myself of that.
RAP Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
